Amanda J. W. Branten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amanda J. W. Branten has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- J F Wetzels
University Hospital Nijmegen, Nijmegen, The Netherlands
4 shared publications Ina S. Klasen
Department of Medicine, Division of Nephrology, and †Department of Clinical Chemistry, University Medical Center, Nijmegen, The Netherlands; ‡Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands; §Department of Internal Medicine, Hospital Rijnstate, Arnhem, The Netherlands; ‖Department of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands; and ¶Department of Internal Medicine, Jeroen Bosch Hospital, ′s-Hertogenbosch, The Netherlands
2 shared publicationsDaan A. Hollander
Department of Medicine, Division of Nephrology, and †Department of Clinical Chemistry, University Medical Center, Nijmegen, The Netherlands; ‡Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands; §Department of Internal Medicine, Hospital Rijnstate, Arnhem, The Netherlands; ‖Department of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands; and ¶Department of Internal Medicine, Jeroen Bosch Hospital, ′s-Hertogenbosch, The Netherlands
1 shared publicationDorine W. Swinkels
1 shared publicationE. M. G. Jacobs
Department of Medicine, University Hospital Nijmegen, The Netherlands
1 shared publicationFrank H. Bosch
Department of Medicine, Division of Nephrology, and †Department of Clinical Chemistry, University Medical Center, Nijmegen, The Netherlands; ‡Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands; §Department of Internal Medicine, Hospital Rijnstate, Arnhem, The Netherlands; ‖Department of Internal Medicine, Hospital Gelderse Vallei, Ede, The Netherlands; and ¶Department of Internal Medicine, Jeroen Bosch Hospital, ′s-Hertogenbosch, The Netherlands
1 shared publication
Latest Publications
- 15 February 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (4) , 707-711
Serum creatinine is a poor marker of GFR in nephrotic syndrome
In daily clinical practice creatinine clearance is used as marker of glomerular filtration rate (GFR). As a result of the tubular secretion process endogenous creatinine clearance (ECC) overestimates glomerular filtration rate, particularly in patients with impaired renal function. It has been suggested that the tubular handling of creatinine is altered in patients with a nephrotic syndrome. Inulin clearance (GFR) and creatinine clearance (ECC) have been simultaneously measured in a cohort of 42 patients with proteinuria and 45 healthy controls. The clearance of creatinine by tubular secretion (TScreat) can be estimated by ECC-GFR. TScreat was calculated in both groups. Regression analysis was performed to identify factors that independently influence tubular creatinine secretion. The mean age (+/-SD) of the patients was 41+/-13 years, serum albumin 26+/-9 g/l, median (IQR) proteinuria 4.5 (3.6-8.2) g/10 mmol creatinine, serum creatinine 103 (84-143) micromol/l, ECC 85 (69-118) ml/min/1.73 m2, and GFR 54 (36-83) ml/min/1.73 m2. Median TScreat amounted to 29 (21-36) ml/min/1.73 m2. In the healthy controls serum creatinine was 75 (70-81) micromol/l, ECC 118 (109-125) ml/min/1.73 m2, GFR 106 (102-115) ml/min/1.73 m2, and TScreat 11 (3.5-19) ml/min/1.73 m2. By regression analysis serum albumin was identified as an independent predictor of tubular creatinine secretion. We divided the patients in two subgroups based on serum albumin levels. TScreat was 24 (14-29) ml/min/1.73 m2 in patients with serum albumin levels >25.8 g/l, and 36 (28-54) ml/min/1.73 m2 in patients with serum albumin levels <25.8 g/l (P<0.01). Serum albumin levels influence tubular creatinine secretion. As a result, the endogenous creatinine clearance as well as estimated GFR using a modified MDRD equation more pronouncedly overestimate glomerular filtration rate in nephrotic syndrome.
- 15 February 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (4) , 707-711
Serum creatinine is a poor marker of GFR in nephrotic syndrome
In daily clinical practice creatinine clearance is used as marker of glomerular filtration rate (GFR). As a result of the tubular secretion process endogenous creatinine clearance (ECC) overestimates glomerular filtration rate, particularly in patients with impaired renal function. It has been suggested that the tubular handling of creatinine is altered in patients with a nephrotic syndrome. Inulin clearance (GFR) and creatinine clearance (ECC) have been simultaneously measured in a cohort of 42 patients with proteinuria and 45 healthy controls. The clearance of creatinine by tubular secretion (TScreat) can be estimated by ECC-GFR. TScreat was calculated in both groups. Regression analysis was performed to identify factors that independently influence tubular creatinine secretion. The mean age (+/-SD) of the patients was 41+/-13 years, serum albumin 26+/-9 g/l, median (IQR) proteinuria 4.5 (3.6-8.2) g/10 mmol creatinine, serum creatinine 103 (84-143) micromol/l, ECC 85 (69-118) ml/min/1.73 m2, and GFR 54 (36-83) ml/min/1.73 m2. Median TScreat amounted to 29 (21-36) ml/min/1.73 m2. In the healthy controls serum creatinine was 75 (70-81) micromol/l, ECC 118 (109-125) ml/min/1.73 m2, GFR 106 (102-115) ml/min/1.73 m2, and TScreat 11 (3.5-19) ml/min/1.73 m2. By regression analysis serum albumin was identified as an independent predictor of tubular creatinine secretion. We divided the patients in two subgroups based on serum albumin levels. TScreat was 24 (14-29) ml/min/1.73 m2 in patients with serum albumin levels >25.8 g/l, and 36 (28-54) ml/min/1.73 m2 in patients with serum albumin levels <25.8 g/l (P<0.01). Serum albumin levels influence tubular creatinine secretion. As a result, the endogenous creatinine clearance as well as estimated GFR using a modified MDRD equation more pronouncedly overestimate glomerular filtration rate in nephrotic syndrome.
- 1 January 2005
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (1) , 169-174
Urinary Excretion of β2-Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy
An accurate prediction of the prognosis of patients with idiopathic membranous nephropathy (iMN) should allow restriction of immunosuppressive treatment to patients who are at highest risk for ESRD. On the basis of retrospective studies, it has previously been suggested that the urinary excretions of β2-microglobulin (Uβ2m) and IgG (UIgG) are useful predictors of renal insufficiency in patients with iMN. The threshold values of 0.5 μg/min (Uβ2m) and 250 mg/24 h (UIgG) have been validated in a new and larger patient cohort. From 1995 onward, 57 patients with iMN (38 men, 19 women; age 48 ± 16 yr), a nephrotic syndrome, and a serum creatinine level ≤1.5 mg/dl were studied prospectively. At baseline, a standardized measurement was carried out to determine renal function and protein excretion. The end point renal death was defined as a serum creatinine exceeding 1.5 mg/dl or a rise of serum creatinine of >50%. Mean (±SD) follow-up was 53 ± 23 mo. Thus far, 25 (44%) of the patients have reached the end point renal death. Multivariate analysis confirmed Uβ2m as the strongest independent predictor for the development of renal insufficiency. Sensitivity and specificity were 88 and 91%, respectively, for Uβ2m, and both were 88% for UIgG. When the excretions of both proteins were combined, specificity improved to 97%. It is concluded that the present data validate the accuracy of Uβ2m and of UIgG in predicting renal outcome in patients with iMN. These markers can be used to guide decisions on the start of immunosuppressive treatment.
- 1 January 2005
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (1) , 169-174
Urinary Excretion of β2-Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy
An accurate prediction of the prognosis of patients with idiopathic membranous nephropathy (iMN) should allow restriction of immunosuppressive treatment to patients who are at highest risk for ESRD. On the basis of retrospective studies, it has previously been suggested that the urinary excretions of β2-microglobulin (Uβ2m) and IgG (UIgG) are useful predictors of renal insufficiency in patients with iMN. The threshold values of 0.5 μg/min (Uβ2m) and 250 mg/24 h (UIgG) have been validated in a new and larger patient cohort. From 1995 onward, 57 patients with iMN (38 men, 19 women; age 48 ± 16 yr), a nephrotic syndrome, and a serum creatinine level ≤1.5 mg/dl were studied prospectively. At baseline, a standardized measurement was carried out to determine renal function and protein excretion. The end point renal death was defined as a serum creatinine exceeding 1.5 mg/dl or a rise of serum creatinine of >50%. Mean (±SD) follow-up was 53 ± 23 mo. Thus far, 25 (44%) of the patients have reached the end point renal death. Multivariate analysis confirmed Uβ2m as the strongest independent predictor for the development of renal insufficiency. Sensitivity and specificity were 88 and 91%, respectively, for Uβ2m, and both were 88% for UIgG. When the excretions of both proteins were combined, specificity improved to 97%. It is concluded that the present data validate the accuracy of Uβ2m and of UIgG in predicting renal outcome in patients with iMN. These markers can be used to guide decisions on the start of immunosuppressive treatment.
- Open Access
- 17 August 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (11) , 2754-2760
Serum ferritin levels are increased in patients with glomerular diseases and proteinuria
Background. Ferritin is a high molecular weight protein which reflects body iron stores, but may also rise in the case of an acute phase response. Recently, ferritin has been identified as a predictive factor in the development and progression of atherosclerosis. This is the first report on serum ferritin levels in patients with proteinuria. Methods. We have analysed the data of 142 male patients with a glomerular disease, and proteinuria exceeding 1 g/day. In all patients, we measured various parameters related to proteinuria, serum ferritin and serum iron. Serum β2-microglobulin and the Modification of Diet in Renal Disease (MDRD) equation were used as measures of the glomerular filtration rate (GFR). Results. Mean age (±SD) was 46±15 years, MDRD-GFR 57±25 ml/min/1.73 m2 and median proteinuria 8.0 g/day [interquartile range (IQR) 3.6–13]. Serum albumin (29±9 g/l) and transferrin levels (1.7±0.5 g/l) were low, and cholesterol levels were elevated (median 7.3, IQR 5.9–9.5 mmol/l). Median serum ferritin was 148 µg/l (IQR 89–282), and exceeded 280 µg/l, the upper limit of normal, in 36 patients (25%). Elevated serum ferritin levels could not be explained by an acute phase response as determined by C-reactive protein, or haemochromatosis (DNA analysis). Regression analysis showed an independent relationship between ferritin levels and serum cholesterol, GFR and serum transferrin. Conclusions. Serum ferritin levels are elevated in patients with overt proteinuria. The independent negative relationship between serum ferritin and transferrin points to a specific process and suggests that increased production of ferritin may compensate for the loss of the iron-binding protein transferrin, thus reducing the amount of free iron. Further studies are needed to elucidate the role of ferritin in patients with proteinuria, especially because of the suggested association between ferritin and atherosclerosis.
- 17 August 2004
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (11) , 2754-2760
Open AccessSerum ferritin levels are increased in patients with glomerular diseases and proteinuria
Background. Ferritin is a high molecular weight protein which reflects body iron stores, but may also rise in the case of an acute phase response. Recently, ferritin has been identified as a predictive factor in the development and progression of atherosclerosis. This is the first report on serum ferritin levels in patients with proteinuria. Methods. We have analysed the data of 142 male patients with a glomerular disease, and proteinuria exceeding 1 g/day. In all patients, we measured various parameters related to proteinuria, serum ferritin and serum iron. Serum β2-microglobulin and the Modification of Diet in Renal Disease (MDRD) equation were used as measures of the glomerular filtration rate (GFR). Results. Mean age (±SD) was 46±15 years, MDRD-GFR 57±25 ml/min/1.73 m2 and median proteinuria 8.0 g/day [interquartile range (IQR) 3.6–13]. Serum albumin (29±9 g/l) and transferrin levels (1.7±0.5 g/l) were low, and cholesterol levels were elevated (median 7.3, IQR 5.9–9.5 mmol/l). Median serum ferritin was 148 µg/l (IQR 89–282), and exceeded 280 µg/l, the upper limit of normal, in 36 patients (25%). Elevated serum ferritin levels could not be explained by an acute phase response as determined by C-reactive protein, or haemochromatosis (DNA analysis). Regression analysis showed an independent relationship between ferritin levels and serum cholesterol, GFR and serum transferrin. Conclusions. Serum ferritin levels are elevated in patients with overt proteinuria. The independent negative relationship between serum ferritin and transferrin points to a specific process and suggests that increased production of ferritin may compensate for the loss of the iron-binding protein transferrin, thus reducing the amount of free iron. Further studies are needed to elucidate the role of ferritin in patients with proteinuria, especially because of the suggested association between ferritin and atherosclerosis.
- 6 June 2003
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (6) , 449-456
Urinary excretion of complement C3d in patients with renal diseases
Introduction Complement‐mediated tubular injury may play an important role in the progression of renal diseases. C3d is a presumed marker of complement activation. Its precursor C3dg has been detected in the urine of patients with membranous nephropathy. However, little is known of the renal handling of C3d or its excretion in other renal diseases.Methods We measured the urinary excretion of albumin, IgG, β2‐microglobulin (β2m), and of complement C3d in patients with tubulo‐interstitial nephritis (TIN; n= 8), in patients with membranous nephropathy (n = 35) and in patients with nonmembranous glomerular diseases (23 nonproliferative and 21 proliferative). Fractional excretions (FE) were calculated using creatinine clearance as marker of GFR.Results C3d was not measurable in the urine of the healthy controls, but was detectable in seven out of eight of the TIN patients (median excretion 0·11 mU min−1, range 0·006–2·4 mU min−1). In these patients the urinary excretion of β2m was clearly elevated (median 26·6 µg min−1, range 1·0–103 µg min−1). The FE of C3d correlated with the FE of β2microglobulin (r = 0·83, P = 0·01), and their ratio amounted to 0·03 (range 0·003–0·06), a value in agreement with the expected sieving coefficient. Urine C3d was detectable in all but three of the patients with glomerular diseases (median excretion 0·36 mU min−1, range 0·004–7·9 mU min−1); C3d‐excretion did not differ between the three subgroups of patients with glomerular diseases. FEC3d correlated with FEIgG (r = 0·88, P < 0·01). The ratio FEC3d/FEβ2m was 0·78 (range 0·04–9·99). Selected patients with membranous nephropathy were re‐analyzed after (partial) remission of proteinuria. Reduction of proteinuria resulted in a decrease of C3d excretion.Conclusion Urinary excretion of C3d is elevated in patients with TIN, most likely as a mere consequence of decreased tubular reabsorption. In patients with glomerular diseases urinary excretion of C3d is increased and related to proteinuria, independent of the underlying glomerular disease. In these patients there is evidence of increased local formation of C3d.
- 6 June 2003
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (6) , 449-456
Urinary excretion of complement C3d in patients with renal diseases
Introduction Complement‐mediated tubular injury may play an important role in the progression of renal diseases. C3d is a presumed marker of complement activation. Its precursor C3dg has been detected in the urine of patients with membranous nephropathy. However, little is known of the renal handling of C3d or its excretion in other renal diseases.Methods We measured the urinary excretion of albumin, IgG, β2‐microglobulin (β2m), and of complement C3d in patients with tubulo‐interstitial nephritis (TIN; n= 8), in patients with membranous nephropathy (n = 35) and in patients with nonmembranous glomerular diseases (23 nonproliferative and 21 proliferative). Fractional excretions (FE) were calculated using creatinine clearance as marker of GFR.Results C3d was not measurable in the urine of the healthy controls, but was detectable in seven out of eight of the TIN patients (median excretion 0·11 mU min−1, range 0·006–2·4 mU min−1). In these patients the urinary excretion of β2m was clearly elevated (median 26·6 µg min−1, range 1·0–103 µg min−1). The FE of C3d correlated with the FE of β2microglobulin (r = 0·83, P = 0·01), and their ratio amounted to 0·03 (range 0·003–0·06), a value in agreement with the expected sieving coefficient. Urine C3d was detectable in all but three of the patients with glomerular diseases (median excretion 0·36 mU min−1, range 0·004–7·9 mU min−1); C3d‐excretion did not differ between the three subgroups of patients with glomerular diseases. FEC3d correlated with FEIgG (r = 0·88, P < 0·01). The ratio FEC3d/FEβ2m was 0·78 (range 0·04–9·99). Selected patients with membranous nephropathy were re‐analyzed after (partial) remission of proteinuria. Reduction of proteinuria resulted in a decrease of C3d excretion.Conclusion Urinary excretion of C3d is elevated in patients with TIN, most likely as a mere consequence of decreased tubular reabsorption. In patients with glomerular diseases urinary excretion of C3d is increased and related to proteinuria, independent of the underlying glomerular disease. In these patients there is evidence of increased local formation of C3d.
- 1 February 1999
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 29 (2) , 109-115
Atrial natriuretic peptide increases albuminuria in type 1 diabetic patients: evidence for blockade of tubular protein reabsorption.
It has been suggested that atrial natriuretic peptide (ANP) contributes to the glomerular hyperfiltration of diabetes mellitus. Infusion of ANP increases the urinary excretion of albumin in patients with type 1 diabetes mellitus (IDDM). Although the increased albuminuria is attributed to a rise in glomerular pressure, alterations in tubular protein handling might be involved. We have studied the effects of ANP in nine microalbuminuric IDDM patients. After obtaining baseline parameters, ANP was infused over a 1-h period (bolus 0.05 μg kg−1, infusion rate 0.01 μg kg−1 min−1). Renal haemodynamics, sodium and water clearance and tubular protein handling were studied. The glomerular filtration rate (GFR) increased from 116.4 ± 8.9 to 128.3 ± 8.8 mL min−1 1.73 m−2, whereas the effective renal plasma flow (ERPF) decreased from 534.3 ± 44.3 to 484.9 ± 33.3 mL min−1 1.73m−2 (P < 0.05). As a result, the filtration fraction was significantly higher during infusion of ANP. ANP attenuated proximal tubular sodium reabsorption. Urinary albumin excretion rose from 87.57 ± 21.03 to 291.40 ± 67.86 μg min−1 (P < 0.01). Changes in the urinary excretion of β2-microglobulin and free κ-light chains were more marked, the excretion of β2-microglobulin increasing from 0.28 ± 0.21 to 51.87 ± 10.51 μg min−1 (P < 0.01), and of free κ-light chains from 4.73 ± 1.74 to 46.14 ± 6.19 μg min−1 (P < 0.01). The observed rise in albuminuria during infusion of ANP does not simply reflect a change in glomerular pressure, but might at least partly result from an attenuation of tubular protein reabsorption.
- 1 February 1999
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 29 (2) , 109-115
Atrial natriuretic peptide increases albuminuria in type 1 diabetic patients: evidence for blockade of tubular protein reabsorption.
It has been suggested that atrial natriuretic peptide (ANP) contributes to the glomerular hyperfiltration of diabetes mellitus. Infusion of ANP increases the urinary excretion of albumin in patients with type 1 diabetes mellitus (IDDM). Although the increased albuminuria is attributed to a rise in glomerular pressure, alterations in tubular protein handling might be involved. We have studied the effects of ANP in nine microalbuminuric IDDM patients. After obtaining baseline parameters, ANP was infused over a 1-h period (bolus 0.05 μg kg−1, infusion rate 0.01 μg kg−1 min−1). Renal haemodynamics, sodium and water clearance and tubular protein handling were studied. The glomerular filtration rate (GFR) increased from 116.4 ± 8.9 to 128.3 ± 8.8 mL min−1 1.73 m−2, whereas the effective renal plasma flow (ERPF) decreased from 534.3 ± 44.3 to 484.9 ± 33.3 mL min−1 1.73m−2 (P < 0.05). As a result, the filtration fraction was significantly higher during infusion of ANP. ANP attenuated proximal tubular sodium reabsorption. Urinary albumin excretion rose from 87.57 ± 21.03 to 291.40 ± 67.86 μg min−1 (P < 0.01). Changes in the urinary excretion of β2-microglobulin and free κ-light chains were more marked, the excretion of β2-microglobulin increasing from 0.28 ± 0.21 to 51.87 ± 10.51 μg min−1 (P < 0.01), and of free κ-light chains from 4.73 ± 1.74 to 46.14 ± 6.19 μg min−1 (P < 0.01). The observed rise in albuminuria during infusion of ANP does not simply reflect a change in glomerular pressure, but might at least partly result from an attenuation of tubular protein reabsorption.
- 1 January 1999
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 59 (2) , 133-137
Infusion of plasma expanders may lead to unexpected results in urinary protein assays
Overt proteinuria was detected in the urine of a potential kidney donor, ultimately leading to the refusal of the kidneys for transplantation purposes. Histological examination of the kidneys did not reveal any abnormalities. Searching for substances that could have interfered with the urinary total protein assay, the role of infused, modified gelatin plasma expanders was investigated. We therefore measured the concentration of protein before and after the addition of various artificial plasma expanders to urine. Only when Biuret reagent or Pyrogallol Red dye were used did we find elevated concentrations of protein. Other methods, including the turbidimetric assays, did not detect additional amounts of protein in the spiked urine. We conclude that the infusion of modified gelatin solutions may cause apparent proteinuria. This effect is not observed with starch-based plasma expanders. Clinical chemists and clinicians should be aware of this phenomenon and possibly repeat the analysis with a different technique.
- 1 January 1999
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 59 (2) , 133-137
Infusion of plasma expanders may lead to unexpected results in urinary protein assays
Overt proteinuria was detected in the urine of a potential kidney donor, ultimately leading to the refusal of the kidneys for transplantation purposes. Histological examination of the kidneys did not reveal any abnormalities. Searching for substances that could have interfered with the urinary total protein assay, the role of infused, modified gelatin plasma expanders was investigated. We therefore measured the concentration of protein before and after the addition of various artificial plasma expanders to urine. Only when Biuret reagent or Pyrogallol Red dye were used did we find elevated concentrations of protein. Other methods, including the turbidimetric assays, did not detect additional amounts of protein in the spiked urine. We conclude that the infusion of modified gelatin solutions may cause apparent proteinuria. This effect is not observed with starch-based plasma expanders. Clinical chemists and clinicians should be aware of this phenomenon and possibly repeat the analysis with a different technique.
- 26 December 1998
- Vol. 142 (52) , 2832-8
[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy].
Prednisone monotherapy is the treatment of choice for patients with a nephrotic syndrome due to minimal change glomerulopathy. In adult patients treatment should be continued for at least 24 weeks. Within this period a remission of proteinuria will occur in 75 to 90% of the patients. Patients who do not respond satisfactorily to prednisone treatment can be treated with alkylating agents. Cyclophosphamide is the drug used most commonly. Prolonged treatment (> 12 weeks) is associated with a high risk of infertility. If alkylating agents cannot be used, prolonged treatment with ciclosporine is an option.
- 26 December 1998
- Vol. 142 (52) , 2832-8
[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy].
Prednisone monotherapy is the treatment of choice for patients with a nephrotic syndrome due to minimal change glomerulopathy. In adult patients treatment should be continued for at least 24 weeks. Within this period a remission of proteinuria will occur in 75 to 90% of the patients. Patients who do not respond satisfactorily to prednisone treatment can be treated with alkylating agents. Cyclophosphamide is the drug used most commonly. Prolonged treatment (> 12 weeks) is associated with a high risk of infertility. If alkylating agents cannot be used, prolonged treatment with ciclosporine is an option.
- 4 April 1998
- Vol. 142 (14) , 767-72
[Immunosuppressive therapy for idiopathic membranous glomerulopathy].
Idiopathic membranous nephropathy is the most frequent cause of nephrotic syndrome in adults. The natural course of idiopathic membranous nephropathy is characterized by a high incidence of spontaneous remissions. Some 50% of the patients reach end-stage renal disease. Treatment with corticosteroids alone is not efficacious; treatment with a combination of immunosuppressive drugs improves renal survival. However, because of the high incidence of spontaneous remissions and the risk of treatment-related toxicity, immunosuppressive treatment should be reserved for patients with proven renal insufficiency. Cyclophosphamide appears to be more efficacious and better tolerated than chlorambucil. Identification of high-risk patients at an early stage of the renal disease may contribute to a more efficient use of immunosuppressive treatment.
- 4 April 1998
- Vol. 142 (14) , 767-72
[Immunosuppressive therapy for idiopathic membranous glomerulopathy].
Idiopathic membranous nephropathy is the most frequent cause of nephrotic syndrome in adults. The natural course of idiopathic membranous nephropathy is characterized by a high incidence of spontaneous remissions. Some 50% of the patients reach end-stage renal disease. Treatment with corticosteroids alone is not efficacious; treatment with a combination of immunosuppressive drugs improves renal survival. However, because of the high incidence of spontaneous remissions and the risk of treatment-related toxicity, immunosuppressive treatment should be reserved for patients with proven renal insufficiency. Cyclophosphamide appears to be more efficacious and better tolerated than chlorambucil. Identification of high-risk patients at an early stage of the renal disease may contribute to a more efficient use of immunosuppressive treatment.